Currently Viewing:
American Society of Hematology
Julie Wolfson: Supporting AYAs Before and After Treatment
January 14, 2018
Dr Julie Wolfson on What Clinicians Need to Understand About Adolescents/Young Adults With ALL
December 30, 2017
Currently Reading
Dr Nina Shah on the Impact of New Treatments for Multiple Myeloma
December 29, 2017
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25, 2017
Diagnosing Congenital Neutropenia
December 23, 2017
Dr Derek Raghavan: Ensuring Guidelines Are Implemented and Followed
December 22, 2017
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 18, 2017
Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs
December 18, 2017
Diagnosing Non-Chemotherapy Drug-Induced Neutropenia
December 16, 2017
Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma
December 12, 2017
New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study
December 12, 2017
Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children
December 12, 2017
Dr Joshua Richter Discusses Patient Financial Burden of New Treatments and Cures
December 12, 2017
CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients
December 11, 2017
Dr Thomas LeBlanc: Patients With Blood Cancers Less Likely to Use Hospice Care
December 11, 2017
Dr Nina Shah on the Benefits of Outpatient HSCT When Possible
December 11, 2017
Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH
December 11, 2017
CTL019 More Cost Effective in Pediatric Patients With Acute Lymphoblastic Lymphoma
December 11, 2017
Balancing Hospice Utilization With the Need for Transfusion in Leukemia
December 11, 2017

Dr Nina Shah on the Impact of New Treatments for Multiple Myeloma

The last 5 years have seen a host of new drugs approved for multiple myeloma, improving survival times for patients, explained Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.


The last 5 years have seen a host of new drugs approved for multiple myeloma, improving survival times for patients, explained Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.

Transcript

What has been the biggest change in the last 5 years in multiple myeloma treatment?

There have been so many changes in multiple myeloma. Number one, we’ve had a host of new drugs approved. Some of them are better drugs for the same mechanism of action. And some of them are new types of drugs and I’d say the new types of drugs have really been focused on immunotherapies, that being antibodies against specific proteins on the myeloma cells and that’s really changed the way we treat relapsed myeloma.

How have new multiple myeloma treatments impacted survival and other outcomes?

Well, we know that we’re doing a better job. We know that patients that are treated over the past 5 to 10 years are doing better than those treated before, and that’s really encouraging to us and part of that, most of that reason, is because of all these new drugs. We’re really thankful to all the patients for participating in clinical trials to help this along. I think that people who are diagnosed with myeloma now really can say that they’ll survive longer than those who had been diagnosed before. And that’s because of these new drugs.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!